Seven years ago, the landscape of interventional psychiatry was sparse, struggling to accommodate the logistical demands of innovative, non-traditional therapies. When Johnson & Johnson introduced Spravato (esketamine), a ketamine-based nasal spray for treatment-resistant depression, the medical community faced a daunting "infrastructure gap." There were simply not enough clinics equipped with the specialized staff, observation space, and regulatory expertise required to administer a drug that necessitated hours of clinical monitoring.
Catherine Owen-Adams, a former president in J&J’s Janssen division, famously characterized that era as "very underdeveloped," noting that the market required a "huge investment" to become viable. Today, that investment has proven to be a watershed moment for mental health. Spravato generated over $1 billion in the first half of 2026 alone, and the United States now boasts approximately 8,500 interventional psychiatry clinics. This evolution has paved the way for the next, and arguably more complex, frontier: the integration of psychedelic-based medicines into standard psychiatric practice.
The Evolution of Interventional Psychiatry: A Chronology of Access
To understand the current readiness of the healthcare system, one must examine the progression of the last decade:
- 2019: The FDA approves Spravato. At the time, only a handful of clinics nationwide possess the capability to handle in-office, multi-hour patient observation.
- 2020–2024: A period of "anticipatory infrastructure building." Independent clinics begin expanding their footprints, hiring multidisciplinary teams, and refining reimbursement models, driven by the belief that psychedelic therapies will eventually receive regulatory approval.
- 2025: The "infrastructure boom" reaches critical mass. The number of specialized interventional clinics swells to 8,500, with many centers operating at partial capacity, waiting for the next generation of therapies to arrive.
- 2026: Compass Pathways, a U.K.-based biotech, announces it is in the final stages of its FDA application for "COMP360," a synthetic psilocybin compound. The company anticipates completing its regulatory filing in the fourth quarter.
Supporting Data: Why the Infrastructure is Ready
The skepticism surrounding the rollout of psychedelics often centers on the "observation burden." Unlike traditional antidepressants—which are dispensed via a pharmacy and taken at home—COMP360 requires a six- to eight-hour observation period in a controlled environment.
Critics have long argued that primary care physicians, already constrained by 15-minute appointment windows, could never accommodate such a protocol. However, leadership at Compass Pathways contends that the industry has fundamentally shifted away from the traditional primary care model for these specific indications.
"If we were counting on the places where the bulk of antidepressants are written—primary care—you’re exactly right; that would not fit," says Steve Levine, Chief Patient Officer at Compass Pathways. "But we aren’t. We are tapping into a network of 8,500 clinics that have already been built for interventional psychiatry. Many of these centers have built capacity ahead of time, anticipating approvals like ours."
Furthermore, the economic framework has been stress-tested. The reimbursement models established by Spravato have created a roadmap for future therapies. Regardless of the duration of the visit, these sites are now equipped to bill for the time clinicians spend monitoring patients. Compass Pathways expects their reimbursement rates to be competitive, if not superior, to those currently enjoyed by Spravato providers.
Official Perspectives: The Compass Pathways Strategy
In a recent conversation with BioPharma Dive, Compass CEO Kabir Nath and CPO Steve Levine outlined their go-to-market strategy. The company is taking a "go slow to go fast" approach, focusing on a highly managed, contained launch to ensure that initial patient experiences are flawless.
The "Drag and Drop" Model
Compass describes their treatment as "drag and drop." Because the existing interventional clinics are already staffed with a mix of medical assistants, nurses, and psychologists, the clinical workflow for COMP360 is essentially identical to current procedures. Multiple rooms can operate simultaneously, allowing for a scalable, team-based model that does not require a psychiatrist to be present for every minute of the eight-hour window.
Commercial Expansion
Compass has aggressively scaled its commercial team, growing from just 20 employees at the start of 2026 to over 100 today. However, the company is exercising disciplined restraint regarding its field-facing sales force. "It doesn’t make sense to make that investment just in case there’s a rejection or a delay," Nath explained. The company intends to hire the final, frontline sales staff only once the FDA greenlight is officially in hand.
Implications: Addressing the Adherence and Competition Conundrum
One of the greatest challenges in psychiatry is patient adherence. Traditional SSRIs (Selective Serotonin Reuptake Inhibitors) are plagued by daily burdens: the need for constant memory, the occurrence of uncomfortable side effects like weight gain or sexual dysfunction, and the high rate of "accidental" non-compliance.
The Adherence Advantage
Compass argues that the clinical model for COMP360 solves these issues by design.
- In-Office Oversight: Because the dose is administered under supervision, the first dose has 100% adherence.
- Infrequent Dosing: The treatment is projected to be required only one to four times per year.
- Transient Side Effects: Unlike daily medications, side effects for COMP360 are generally mild, transient, and restricted to the day of administration.
The Competitive Landscape
The rise of psychedelic biotechs has created a unique dynamic on Wall Street. While these companies are technically competitors, they are also beneficiaries of a rising tide. "Positive data from any company further validates the field," Nath noted.
He dismissed concerns that COMP360 would cannibalize Spravato’s market share. "There are 100,000 patients on Spravato, which leaves almost 4 million patients taking nothing. We are not asking providers to choose between us and J&J; we are offering incremental business."
Lessons from Recent Market Entrants
When asked about the underwhelming sales performance of other high-profile nervous system drugs—such as Bristol Myers Squibb’s Cobenfy or Vertex’s Journavx—Nath remained optimistic, viewing them as an "apples and oranges" comparison. He attributed the struggles of those drugs to logistical hurdles, such as strict dietary requirements or twice-daily dosing, which do not apply to the infrequent, supervised nature of psilocybin treatment.
"We don’t have the educational hill to climb that those drugs did," added Levine. "People already accept that these drugs work. Our challenge is not proving efficacy; it is simply executing on a new, but entirely ready, delivery infrastructure."
Conclusion: A New Era for Mental Health
As Compass Pathways moves toward its late-2026 filing, the broader implications for the psychiatric industry are clear. The "infrastructure gap" that once threatened to derail psychedelic medicine has been bridged by the success of earlier, ketamine-based treatments. By leveraging a specialized, nationwide network of clinics and focusing on a model that prioritizes clinical outcomes over high-frequency pill-taking, Compass is positioning itself to not just launch a new drug, but to define a new category of medicine—one where the burden of treatment is finally shifting from the patient to the clinic.
